Literature DB >> 31273817

Joint modeling of progression-free and overall survival and computation of correlation measures.

Matthias Meller1, Jan Beyersmann2, Kaspar Rufibach1.   

Abstract

In this paper, we derive the joint distribution of progression-free and overall survival as a function of transition probabilities in a multistate model. No assumptions on copulae or latent event times are needed and the model is allowed to be non-Markov. From the joint distribution, statistics of interest can then be computed. As an example, we provide closed formulas and statistical inference for Pearson's correlation coefficient between progression-free and overall survival in a parametric framework. The example is inspired by recent approaches to quantify the dependence between progression-free survival, a common primary outcome in Phase 3 trials in oncology and overall survival. We complement these approaches by providing methods of statistical inference while at the same time working within a much more parsimonious modeling framework. Our approach is completely general and can be applied to other measures of dependence. We also discuss extensions to nonparametric inference. Our analytical results are illustrated using a large randomized clinical trial in breast cancer.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Keywords:  event history analysis; illness-death model; multistate model; randomized clinical trials

Mesh:

Year:  2019        PMID: 31273817     DOI: 10.1002/sim.8295

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  2 in total

1.  Estimation of time to progression and post progression survival using joint modeling of summary level OS and PFS data with an ordinary differential equation model.

Authors:  Mario Nagase; Sameer Doshi; Sandeep Dutta; Chih-Wei Lin
Journal:  J Pharmacokinet Pharmacodyn       Date:  2022-07-23       Impact factor: 2.410

2.  Design aspects of COVID-19 treatment trials: Improving probability and time of favorable events.

Authors:  Jan Beyersmann; Tim Friede; Claudia Schmoor
Journal:  Biom J       Date:  2021-10-22       Impact factor: 1.715

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.